Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-cash Items: 2020-2025

Historic Non-cash Items for Insight Molecular Diagnostics (IMDX) over the last 2 years, with Sep 2025 value amounting to $306,000.

  • Insight Molecular Diagnostics' Non-cash Items rose 1175.00% to $306,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $306,000, marking a year-over-year increase of 1175.00%. This contributed to the annual value of $246,000 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Non-cash Items stood at $306,000, which was down 21.54% from $390,000 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Non-cash Items registered a high of $19.1 million during Q4 2021, and its lowest value of $51 during Q2 2024.
  • Moreover, its 2-year median value for Non-cash Items was $236,000 (2024), whereas its average is $198,675.
  • Data for Insight Molecular Diagnostics' Non-cash Items shows a peak YoY soared of 764,605.88% (in 2025) over the last 5 years.
  • Over the past 3 years, Insight Molecular Diagnostics' Non-cash Items (Quarterly) stood at $19.1 million in 2021, then reached $24,000 in 2024, then spiked by 1,175.00% to $306,000 in 2025.
  • Its Non-cash Items stands at $306,000 for Q3 2025, versus $390,000 for Q2 2025 and $279,000 for Q1 2025.